Product Description
Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mereo BioPharma
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Kidney Injury|Chronic Obstructive Pulmonary Disease
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03498170 |
MBCT103 | P1 |
Completed |
Healthy Volunteers |
2018-05-03 |
60% |
2019-03-22 |
Treatments |
NCT02926326 |
MBCT102 | P1 |
Completed |
Healthy Volunteers |
2016-10-01 |
2019-03-21 |
Treatments |
|
NCT02700919 |
MBCT206 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-11-08 |
2019-03-20 |
Treatments |
|
2015-004631-13 |
2015-004631-13 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-11-07 |
2025-06-28 |
Treatments |
|
NCT01336959 |
CBCT197A2202 | P2 |
Terminated |
Acute Kidney Injury |
2013-11-01 |
2019-03-19 |
Treatments |
|
2010-021723-27 |
Safety & Efficacy of BCT197A2201 in COPD patients presenting with an exacerbation | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2013-05-14 |
2025-06-29 |
Treatments |
|
NCT01332097 |
CBCT197A2201 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2013-05-01 |
2023-03-22 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/31/2022 |
News Article |
Mereo BioPharma Sends Letter to Rubric Capital Management |
|
03/27/2020 |
News Article |
Business Update and Directorate Change |
|
02/28/2020 |
News Article |
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta |
|
02/19/2020 |
News Article |
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor |